How many 8-K filings has Supernus Pharmaceuticals, Inc. filed?

Supernus Pharmaceuticals, Inc. (SUPN) has 32 8-K (Current Event Report) filings on record, spanning Feb 2024 to Apr 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Supernus Pharmaceuticals, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Supernus Pharmaceuticals, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Supernus Pharmaceuticals, Inc. (SUPN) — 8-K Filings

All 8-K filings from Supernus Pharmaceuticals, Inc.. Browse 32 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (32)

Supernus Pharmaceuticals Completes Asset Acquisition — Apr 7, 2026 Risk: medium
On April 1, 2026, Supernus Pharmaceuticals, Inc. entered into a material definitive agreement and completed the acquisition of assets. The filing details the co
8-K Filing — Nov 4, 2025
Supernus Pharmaceuticals Files 8-K on Financials — Oct 21, 2025 Risk: low
On October 21, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditi
Supernus Pharmaceuticals Reports Officer and Director Changes — Aug 4, 2025 Risk: medium
Supernus Pharmaceuticals, Inc. filed an 8-K on August 4, 2025, reporting changes effective June 16, 2025. The filing details the departure of directors or certa
Supernus Pharmaceuticals Completes Asset Acquisition — Jul 31, 2025 Risk: medium
On July 30, 2025, Supernus Pharmaceuticals, Inc. announced the completion of its acquisition of certain assets from Impel Pharmaceuticals Inc. for an undisclose
Supernus Pharmaceuticals Files 8-K on Financials — Jul 22, 2025 Risk: low
On July 22, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing includes financial
Supernus Pharmaceuticals Files 8-K for Shareholder Vote & Exhibits — Jun 17, 2025 Risk: low
On June 16, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report to announce the submission of matters to a vote of security holders and to file financial s
Supernus Pharmaceuticals Files 8-K — Jun 16, 2025 Risk: medium
On June 13, 2025, Supernus Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The
Supernus Pharmaceuticals Files 8-K — May 28, 2025 Risk: low
On May 22, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No sp
Supernus Pharmaceuticals Files 8-K on Financial Condition — Apr 23, 2025 Risk: low
On April 23, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing results of operations and financial condition. The filing does not contain speci
Supernus Pharmaceuticals Files 8-K on Director Changes — Feb 24, 2025 Risk: low
On February 24, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing incl
Supernus Pharmaceuticals Files 8-K — Feb 18, 2025 Risk: low
On February 18, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine co
Supernus Pharmaceuticals Files 8-K on Financials — Feb 11, 2025 Risk: low
On February 11, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condit
Supernus Pharmaceuticals Files 8-K Report — Feb 4, 2025 Risk: low
On February 4, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," i
Supernus Pharmaceuticals Files 8-K — Jan 27, 2025 Risk: low
On January 27, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine cor
Supernus Pharmaceuticals Files 8-K on Ethics Code and Exhibits — Dec 20, 2024 Risk: low
On December 19, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns amendments to the company's Code of Ethics and the inclu
Supernus Pharmaceuticals Files 8-K for Regulation FD Disclosure — Oct 30, 2024 Risk: medium
On October 30, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing a Regulation FD Disclosure. No speci
Supernus Pharmaceuticals Files 8-K on Financials — Oct 21, 2024 Risk: low
On October 21, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditi
Supernus Pharmaceuticals Files 8-K — Oct 17, 2024 Risk: low
On October 17, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulatio
Supernus Pharmaceuticals Files 8-K — Oct 10, 2024 Risk: low
On October 10, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific mater
Supernus Pharmaceuticals Completes CNS Pharmaceuticals Acquisition — Aug 19, 2024 Risk: medium
On August 19, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company has completed its previously announced acquisition
Supernus Pharmaceuticals Files 8-K Report — Aug 1, 2024 Risk: low
On August 1, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of an event and does not contain specific f
Supernus Pharmaceuticals Files 8-K on Financials — Jul 23, 2024 Risk: low
On July 23, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements an
Supernus Pharmaceuticals Files 8-K — Jun 17, 2024 Risk: low
Supernus Pharmaceuticals, Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing
Supernus Pharmaceuticals Files 8-K — May 23, 2024 Risk: low
Supernus Pharmaceuticals, Inc. filed an 8-K on May 23, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
Supernus Pharmaceuticals Files 8-K — May 9, 2024 Risk: low
On May 9, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating no major new eve
Supernus Pharmaceuticals Announces Board Changes — Apr 24, 2024 Risk: low
On April 22, 2024, Supernus Pharmaceuticals, Inc. announced changes to its Board of Directors, including the election of Dr. Elizabeth H. Shea and Mr. David M.
Supernus Pharmaceuticals Files 8-K with Exhibits — Apr 8, 2024 Risk: low
On April 8, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, indicat
Supernus Pharmaceuticals Reports Officer Compensation & Board Changes — Feb 28, 2024 Risk: medium
Supernus Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, reporting events from February 22, 2024. The filing primarily concerns changes in compensatory
Supernus Pharmaceuticals Reports Executive Changes and Compensation Arrangements — Feb 21, 2024 Risk: low
Supernus Pharmaceuticals, Inc. filed an 8-K on February 21, 2024, reporting an event on February 14, 2024, concerning the departure or election of directors or
Supernus Files 8-K on Financial Results and Exhibits — Feb 13, 2024 Risk: medium
Supernus Pharmaceuticals, Inc. filed an 8-K Current Report with the SEC on February 13, 2024. This filing, with accession number 0001356576-24-000006, specifica
SUPN Files 8-K for 'Other Event'; Routine Admin Update — Feb 5, 2024
Supernus Pharmaceuticals, Inc. filed an 8-K on February 5, 2024, to report an "Other Event." This filing primarily updates administrative details, confirming it

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX